High-dose N-acetylcysteine decreases silica-induced lung fibrosis in the rat

Journal of International Medical Research

Volumn 41, Issue 4, 2013, Pages 1179-1186

  Zhang, Hua ^a   Yin, Gang ^a   Jiang, Hao ^a   Zhang, Chunling ^a  

^a Qingdao Central Hospital   (China)

Author keywords

Lung fibrosis; N acetylcysteine; rat model; silicosis

Indexed keywords

ACETYLCYSTEINE; C REACTIVE PROTEIN; HYDROXYPROLINE; INTERLEUKIN 8; MALONALDEHYDE; SILICON DIOXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; LIPID PEROXIDATION; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG LAVAGE; LUNG PARENCHYMA; MALE; NONHUMAN; PNEUMONIA; PROTEIN BLOOD LEVEL; RAT; SCORING SYSTEM;

EID: 84887374328     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513488503     Document Type: Article

References (30)

1. Davis GS.Pathogenesis of silicosis: current concepts and hypotheses.Lung. 1986;164:139-154.
2. Ma JY,Barger MW,Hubbs AF,et al.Use of tetrandrine to differentiate between mechanisms involved in silica-versus bleomycin-induced fibrosis.J Toxicol Environ Health A. 1999;57:247-266.
3. Cohen R,Velho V.Update on respiratory disease from coal mine and silica dust.Clin Chest Med. 2002;23:811-826.
4. Stey C,Steurer J,Bachmann S,et al.The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.Eur Respir J. 2000;16:253-262.
5. Cotgreave IAAdvances in pharmacology: antioxidants in disease: mechanisms and therapy. Sies H, ed. New York, NY: Academic Press; 1997:205-227.
6. Meyer A,Buhl R,Magnussen H.The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis.Eur Respir J. 1994;7:431-436.
7. Moeller A,Ask K,Warburton D,et al.The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?.Int J Biochem Cell Biol. 2008;40:362-382.
8. Gillissen A,Nowak D.Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy.Respir Med. 1998;92:609-623.
9. Henry JH,Rui-ming L,Li TOxygen, gene expression, and cellular function. Clerch LBDonald JM, ed. New York: Marcel Dekker; 1997:99-121.
10. Day BJ.Antioxidants as potential therapeutics for lung fibrosis.Antioxid Redox Signal. 2008;10:355-370.
11. Bridgeman MM,Marsden M,MacNee W,et al.Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine.Thorax. 1991;46:39-42.
12. Bridgeman MM,Marsden M,Selby C,et al.Effect of N-acetylcysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue.Thorax. 1994;49:670-675.
13. Meyer A,Buhl R,Magnussen H.The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis.Eur Respir J. 1994;7:431-436.
14. Leeder RG,Brien JF,Massey TE.Investigation of the role of oxidative stress in amiodarone-induced pulmonary toxicity in the hamster.Can J Physiol Pharmacol. 1994;72:613-621.
15. Neal R,Matthews RH,Lutz P,et al.Antioxidant role of N-acetyl cysteine isomers following high dose irradiation.Free Radic Biol Med. 2003;34:689-695.
16. Ashcroft T,Simpson JM,Timbrell V.Simple method of estimating severity of pulmonary fibrosis on a numerical scale.J Clin Pathol. 1988;41:467-470.
17. Driscoll KE,Guthrie GDComprehensive toxicology: toxicology of the respiratory system. Roth RA, ed. New York: Elsevier Science; 1997:373-391.
18. Driscoll KE,Lindenschmidt RC,Maurer JK,et al.Pulmonary response to silica or titanium dioxide: inflammatory cells, alveolar macrophage-derived cytokines, and histopathology.Am J Respir Cell Mol Biol. 1990;2:381-390.
19. Piguet PF,Collart MA,Grau GE,et al.Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis.Nature. 1990;344:245-247.
20. Driscoll KESilica and silica-induced lung diseases. Castranova VVallyathan VWallace WE, ed. CRC Press: Boca Raton; 1996:163-184.
21. Kennedy T,Ghio AJ,Reed W,et al.Copper-dependent inflammation and nuclear factor-kappaB activation by particulate air pollution.Am J Respir Cell Mol Biol. 1998;19:366-378.
22. Zhang Y,Lee TC,Guillemin B,et al.Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure.J Immunol. 1993;150:4188-4196.
23. Kline JN,Schwartz DA,Monick MM,et al.Relative release of interleukin-1 beta and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis.Chest. 1993;104:47-53.
24. Schwartz DA,Galvin JR,Frees KL,et al.Clinical relevance of cellular mediators of inflammation in workers exposed to asbestos.Am Rev Respir Dis. 1993;148:68-74.
25. Hnizdo E,Vallyathan V.Chronic obstructive pulmonary disease due to occupational exposure to silica dust: a review of epidemiological and pathological evidence.Occup Environ Med. 2003;60:237-243.
26. Castranova V,Vallyathan V.Silicosis and coal workers' pneumoconiosis.Environ Health Perspect. 2000;108:675-684.
27. Hubbard AK,Timblin CR,Shukla A,et al.Activation of NF-kappaB-dependent gene expression by silica in lungs of luciferase reporter mice.Am J Physiol Lung Cell Mol Physiol. 2002;282:L968-L975.
28. Hubbard AK,Timblin CR,Rincon M,et al.Use of transgenic luciferase reporter mice to determine activation of transcription factors and gene expression by fibrogenic particles.Chest. 2001;120 (Suppl 1): 24S-25S.
29. Brennan FM,Maini RN,Feldmann M.Cytokine expression in chronic inflammatory disease.Br Med Bull. 1995;51:368-384.
30. Rahman I,MacNee W.Role of transcription factors in inflammatory lung diseases.Thorax. 1998;53:601-612.